Abstract
1685
Objectives VEGF receptor (VEGFR) is known to be associated with advanced tumor growth and the induction of tumor angiogenesis and is also shown to be over-expressed in various human tumors. Therefore, expression levels of the receptor could be a valuable indicator of tumor diagnosis and response to anticancer treatment. In the present study, we prepared and evaluated 68Ga-NOTA-VEGF121 for the in vivo imaging of VEGFR expression.
Methods NOTA-VEGF121 was prepared by conjugation of recombinant human VEGF121 (PeproTech) and p-SCN-Bn-NOTA (Macrocyclics) and then purified using a PD-10 column. The NOTA-VEGF121 was radiolabeled with 68Ga at room temperature for 30 min, and the product was purified using a PD-10 column. In vitro cell binding affinity was assessed by incubating 68Ga-NOTA-VEGF121 with U87MG cells at 37 oC for 1, 2, or 4 h (n = 3). For the blocking study, the cells were incubated with 68Ga-NOTA-VEGF121 in the presence of human VEGFR-2 antibody (5 μg/mL) for 2 h. For microPET imaging, 68Ga-NOTA-VEGF121 was injected into mice bearing U87MG cells. Static microPET images were acquired for 20 min at 1 h, 2 h, and 4 h post-injection, and the images were reconstructed using 3D-OSEM. ROIs were drawn over the tumors and the average signal level in the ROIs was measured.
Results The overall radiochemical yield of 68Ga-NOTA-VEGF121 was 40-50% after purification and the radiochemical purity was higher than 98%. The average number of NOTA conjugated to VEGF121 was 0.9-1. In the cell binding study, 68Ga-NOTA-VEGF121 was found to be taken up by the U87MG cells in a time-dependent manner (195% at 2 h and 230% at 4 h; relative to a value of 100% at 1 h). Tumor uptake of 68Ga-NOTA-VEGF121 was slightly blocked in the presence of VEGFR-2 antibody. In microPET images, tumors were clearly visualized and their ROI analyses revealed 3.7% ID/g at 1 h and 4.6% ID/g at 2 h post-injection.
Conclusions The preliminary result suggests that 68Ga-NOTA-VEGF121 has potential for the in vivo imaging of VEGFR expression